Perinatal outcome in women treated with progesterone for the prevention of preterm birth: A meta-analysis

Ultrasound in Obstetrics and Gynecology

Volumn 40, Issue 3, 2012, Pages 257-266

  Sotiriadis, A ^a   Papatheodorou, S ^b   Makrydimas, G ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

neonatal outcome; preterm birth; progesterone

Indexed keywords

PROGESTERONE;

ARTICLE; FEMALE; HUMAN; META ANALYSIS; PERINATAL MORTALITY; PREGNANCY; PREGNANCY OUTCOME; PREMATURITY;

FEMALE; HUMANS; PERINATAL MORTALITY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE BIRTH; PROGESTERONE;

EID: 84865459527     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.11178     Document Type: Article

References (41)

1. Celik E, To M, Gajewska K, Smith GC, Nicolaides KH,; Fetal Medicine Foundation Second Trimester Screening Group. Cervical length and obstetric history predict spontaneous preterm birth: development and validation of a model to provide individualized risk assessment. Ultrasound Obstet Gynecol 2008; 31: 549-554.
2. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S,; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385.
3. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH,. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007; 357: 462-469.
4. Campbell S,. Universal cervical-length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option. Ultrasound Obstet Gynecol 2011; 38: 1-9.
5. Norwitz ER, Caughey AB,. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol 2011; 4: 60-72.
6. Elizur SE, Tulandi T,. Drugs in infertility and fetal safety. Fertil Steril 2008; 89: 1595-1602.
7. FDA. FDA statement on Makena. (http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm249025htm) 2011; Assessed 25/03/2012.
8. Schulz KF, Altman DG, Moher D,; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010; 7: e1000251.
9. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA,; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
10. Barfield WD,; Committee on Fetus and Newborn. Standard terminology for fetal, infant, and perinatal deaths. Pediatrics 2011; 128: 177-181.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
12. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko D, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW,; PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011; 38: 18-31.
13. Cetingoz E, Cam C, Sakalli M, Karateke A, Celik C, Sancak A,. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. Arch Gynecol Obstet 2011; 283: 423-429.
14. Ibrahim M, Ramy A, Ramy M, Younis M,. Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertil Soc J 2010; 15: 39-41.
15. Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S,. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009; 104: 40-43.
16. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Soma-Pillay P, Porter K, How H, Schakis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW,. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 697-705.
17. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, Soma-Pillay P, Porter K, How H, Schackis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW,. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 687-696.
18. Combs CA, Garite T, Maurel K, Das A, Porto M,; Obstetrix Collaborative Research Network. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 2011; 204: 221.e1-8.
19. Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJ, van Eyck J, Groenwold RH, Hasaart TH, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BW, Bruinse HW,. 17alpha-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. Obstet Gynecol 2011; 118: 513-520.
20. Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A,; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011; 38: 272-280.
21. Briery CM, Veillon EW, Klauser CK, Martin RW, Chauhan SP, Magann EF, Morrison JC,. Progesterone does not prevent preterm births in women with twins. South Med J 2009; 102: 900-904.
22. Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, Calder A, Mires G, Danielian P, Sturgiss S, MacLennan G, Tydeman G, Thornton S, Martin B, Thornton JG, Neilson JP, Norrie J,. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet 2009; 373: 2034-2040.
23. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, Malone F, Iams JD, Mercer BM, Thorp J, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M, Anderson G,; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007; 357: 454-461.
24. Hartikainen-Sorri AL, Kauppila A, Tuimala R,. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980; 56: 692-695.
25. Combs CA, Garite T, Maurel K, Das A, Porto M,; Obstetrix Collaborative Research Network. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 2010; 203: 248.e1-9.
26. Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY, Iams JD, Wapner RJ, Varner M, Carpenter M, Lo J, Thorp J, Mercer BM, Sorokin Y, Harper M, Ramin S, Anderson G,; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU). Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 2009; 113: 285-292.
27. Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR,. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000; 106: 659-671.
28. Marlow N, Wolke D, Bracewell MA, Samara M,; EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005; 352: 9-19.
29. Larroque B, Bréart G, Kaminski M, Dehan M, André M, Burguet A, Grandjean H, Ledésert B, Lévêque C, Maillard F, Matis J, Rozé JC, Truffert P,; Epipage study group. Survival of very preterm infants: Epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed 2004; 89: F139-144.
30. Ancel PY, Livinec F, Larroque B, Marret S, Arnaud C, Pierrat V, Dehan M, N'Guyen S, Escande B, Burguet A, Thiriez G, Picaud JC, André M, Bréart G, Kaminski M,; EPIPAGE Study Group. Cerebral palsy among very preterm children in relation to gestational age and neonatal ultrasound abnormalities: the EPIPAGE cohort study. Pediatrics 2006; 117: 828-835.
31. Larroque B, Ancel PY, Marret S, Marchand L, André M, Arnaud C, Pierrat V, Rozé JC, Messer J, Thiriez G, Burguet A, Picaud JC, Bréart G, Kaminski M,; EPIPAGE Study group. Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study. Lancet 2008; 371: 813-820.
32. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M,. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419-424.
33. Klein K, Rode L, Nicolaides KH, Krampl-Bettelheim E, Tabor A,. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol 2011; 38: 281-287.
34. Ventolini G, Duke J, Po W, Barhan S, Rhea D, Desch C, Istwan N, Stanziano G,. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate. J Reprod Med 2008; 53: 667-671.
35. Caritis SN, Sharma S, Venkataramanan R, Rouse DJ, Peaceman AM, Sciscione A, Spong CY, Varner MW, Malone FD, Iams JD, Mercer BM, Thorp JM Jr, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M,; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. Am J Obstet Gynecol 2011; 205: 40.e1-8.
36. Soloff MS, Jeng YJ, Izban MG, Sinha M, Luxon BA, Stamnes SJ, England SK,. Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci 2011; 18: 781-797.
37. Norman JE, Yuan M, Anderson L, Howie F, Harold G, Young A, Jordan F, McInnes I, Harnett MM,. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reprod Sci 2011; 18: 435-446.
38. Lei K, Chen L, Cryar BJ, Hua R, Sooranna SR, Brosens JJ, Bennett PR, Johnson MR,. Uterine stretch and progesterone action. J Clin Endocrinol Metab 2011; 96: E1013-1024.
39. van Os MA, van der Ven JA, Kleinrouweler CE, Pajkrt E, de Miranda E, van Wassenaer A, Porath M, Bossuyt PM, Bloemenkamp KW, Willekes C, Woiski M, Oudijk MA, Bilardo KM, Sikkema MJ, Duvekot JJ, Veersema D, Laudy J, Kuiper P, de Groot CJ, Mol BW, Haak MC,. Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study. BMC Pregnancy Childbirth 2011; 11: 77.
40. Schuit E, Stock S, Groenwold RH, Maurel K, Combs CA, Garite T, Spong CY, Thom EA, Rouse DJ, Caritis SN, Saade GR, Zachary JM, Norman JE, Rode L, Klein K, Tabor A, Cetingöz E, Morrison JC, Magann EF, Briery CM, Serra V, Perales A, Meseguer J, Nassar AH, Lim AC, Moons KG, Kwee A, Mol BW,. Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta-analysis of randomized trials. BMC Pregnancy Childbirth 2012; 12: 13.
41. KV Pharmaceutical Company R-M. A Prospective, Non Intervention Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth. In: Clinical Trials gov [Internet] Bethesda (MD): National Library of Medicine (US) 2000-(cited 2012 Mar 25) Available from: http://clinicaltrialsgov/ct2/show/NCT01146990 NLM identifier: NCT01146990 2012.